Cingulate (CINGW) Total Liabilities (2021 - 2026)
Cingulate's (CINGW) quarterly Total Liabilities came in at $9.6 million in Q2 2026, up 104.0% on a YoY basis from $4.7 million in Q2 2025, and down 23.6% quarter-over-quarter from $12.6 million in Q4 2025.
Analysis
Cingulate (CINGW) Total Liabilities (2021 - 2026) Analysis & Trends
Cingulate (CINGW) has reported Total Liabilities for 6 consecutive years, with $9.6 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Total Liabilities rose 104.0% year-over-year to $9.6 million; the trailing twelve-month figure through Jun 2026 stood at $9.6 million (up 104.0% YoY), and the FY2025 full-year result was $12.6 million, up 69.58% from the prior year.
- Total Liabilities fell to $9.6 million in Q2 2026 per CINGW's latest filing, from $12.6 million in the prior quarter.
- Across five years, Total Liabilities topped out at $12.6 million in Q4 2025 and bottomed at -$240.0 million in Q2 2025.
- Historically, Total Liabilities has averaged -$8.1 million across 5 years, with a median of $7.0 million in 2022.
- The sharpest annual moves came in 2023 and 2025: Total Liabilities surged 599.57% in 2023, then tumbled 11846.65% in 2025.
- Over 5 years, Total Liabilities stood at $7.5 million in 2022, then surged by 37.72% to $10.4 million in 2023, then fell by 28.49% to $7.4 million in 2024, then jumped by 69.58% to $12.6 million in 2025, then fell by 23.6% to $9.6 million in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $9.6 million, $12.6 million, and $7.0 million for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 644.46 Bn | 623.70 Bn | 17.26 Bn | 116.09 Bn |
| 2 | AbbVie | 440.11 Bn | 433.54 Bn | 12.70 Bn | 141.05 Bn |
| 3 | Merck | 365.04 Bn | 357.90 Bn | 12.21 Bn | 23.74 Bn |
| 4 | Novartis Ag | 266.82 Bn | 259.13 Bn | 11.24 Bn | 80.09 Bn |
| 5 | Pfizer | 159.14 Bn | 147.45 Bn | 10.94 Bn | 115.64 Bn |
| 6 | Sanofi | 52.47 Bn | 45.09 Bn | 10.79 Bn | 69.15 Bn |
| 7 | Revolution Medicines | 44.26 Bn | 44.26 Bn | - | 1.72 Bn |
| 8 | Incyte | 25.32 Bn | 20.79 Bn | 1.57 Bn | 1.53 Bn |
| 9 | United Therapeutics | 21.46 Bn | 18.80 Bn | 683.80 Mn | 819.80 Mn |
| 10 | Cingulate | 100,214.03 | 100,214.03 | - | 9.60 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 9.60 Mn |
| Dec 31, 2025 | 12.56 Mn |
| Sep 30, 2025 | 7.05 Mn |
| Jun 30, 2025 | -240.00 Mn |
| Mar 31, 2025 | 6.54 Mn |
| Dec 31, 2024 | 7.41 Mn |
| Sep 30, 2024 | 1.54 Mn |
| Jun 30, 2024 | 2.04 Mn |
| Mar 31, 2024 | 2.28 Mn |
| Dec 31, 2023 | 10.36 Mn |
| Sep 30, 2023 | 5.97 Mn |
| Jun 30, 2023 | 11.33 Mn |
| Mar 31, 2023 | 7.08 Mn |
| Dec 31, 2022 | 7.52 Mn |
| Sep 30, 2022 | 7.01 Mn |
| Jun 30, 2022 | 1.62 Mn |
| Mar 31, 2022 | 2.41 Mn |
| Dec 31, 2021 | 2.04 Mn |
| Sep 30, 2021 | -3.08 Mn |
| Jun 30, 2021 | -1.90 Mn |